An Update on FDA’s Good Laboratory Practice

–Published on August 24, 2016 (81 FR 58342) –Considered ANPRM comments and consistency with relevant OECD documents –Comment period closed on January 21, 2017 •90 day comment period •60 day extension –78 commenters –Multiple comments per submission www.fda.gov

  Code, 2016, Update

I. Pulmonary Toxicology The Nanotoxicology Research ...

1 The Nanotoxicology Research Program in NIOSH Vincent Castranova, PhD NIOSH Nanotoxicology Research Program I. Pulmonary Toxicology (8 projects) II.

  Research, Programs, Niosh, Nanotoxicology, The nanotoxicology research program in niosh

Nanotoxicology Specialty Section - Society of Toxicology

2011 Nanotoxicology Specialty SectionÑ293 members SOT Annual meetingÑ 2 workshops, 1 roundtable, 1 CE, 2 platforms, 4 poster sessions Pre-history 2011

  Specialty, Nanotoxicology, Nanotoxicology specialty

Genotoxic impurities in small molecule drug candidates

Assessment of Genotoxic Impurities in Small Molecule Drug Candidates John Wisler, PhD, DABT Kurt A Black, Ph.D, DABT Comparative Biology and Safety Sciences, Amgen Inc.

  Drug, Impurities, Small, Molecules, Genotoxic, Genotoxic impurities in small molecule drug

SOT Abstract Submission Instructional Guide 2022

3 Enter the Abstract Submission Site Returning users: If you submitted a scientific session proposal or abstract for previous SOT Annual Meetings, you should use the same Login— usually your email address—and Password). Please note this system is separate from the SOT member section of the website and requires

  Proposal, Submissions

Regulatory Toxicology - Society of Toxicology

Overview/Objectives ... Duration of Repeat Dose Toxicology Studies Depends on Clinical Trial Duration . ICH M3 (R2) Non -Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals (2009) Industrial chemicals: Driven by production volume/import tonnage (ECHA 2014)

  Regulatory, Clinical, Overview, Trail, Clinical trials, Authorisation

Tox considerations for oligonucleotide therapeutics

•Key considerations in preclinical testing - Pharmacological species restriction – Use of murine surrogate of the same ... Concentration-dependent prolongation of aPTT Single-dose, 4-hour Infusion 0.1 1 10 100 1000 0 1 4 4.25 4.5 5 8 12 16 28 52 76 100 168 340 Hours Post-dose 20K PEG-aptamer (ug oligo/mL) 25 35 45 55 65 75 aPTT (sec)

  Testing, Therapeutic, Considerations, Oligonucleotide, Tpat, Considerations for oligonucleotide therapeutics

第11回 諸外国の化学物質管理 - NITE

oecdとniteのつながり •nite職員がoecd環境健康安全課（ehs）に出向中 （主にqsarプロジェクト及びcocap（qsar）を担当） •2015年10月にehs課長と会合実施 環境健康安全プログラムに関する職員向け勉強会での 講演 15

  Code

化学品の分類と表示に関する 国際調和（GHS）

2 ghsで何が変わる？ トルエン メチルベンゼン、 cas no. 108-88-3 警告 •可燃性液体 • 飲み込んだり、吸ったり、皮膚につくと有害